Breaking News, Financial News

Merck 3Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck 3Q Revenues: $6.1 billion (+12%) 3Q Earnings: $1.5 billion (+62%) YTD Revenues: $18.0 billion (+8%) YTD Earnings: $4.9 billion (+24%) Comments: Singulair sales rose 17% to $1 billion. Diabetes treatment Januvia, launched in October 2006, posted $185 million in 3Q07 sales. Gardasil, the HPV vaccine approved in the U.S. in June 2006, posted worldwide sales of $418 million. Sales of Zetia and Vytorin are not recognized as revenues, but as equity from a joint venture. The choles...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters